MedTrace Logo

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies

NCT00055575 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2021-03-22

No results posted yet for this study

Summary

This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.

Conditions

Interventions

DRUG

Scopolamine Nasal Spray

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Carlos A Zarate, M.D. · National Institute of Mental Health (NIMH)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-02-27
Primary Completion
2015-02-02
Completion
2015-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055575 on ClinicalTrials.gov